Biopharmaceutical Industry Statement at Gavi, the Vaccine Alliance – Global Vaccine Summit 2020
Geneva, 4 June 2020
Statement delivered by: Thomas Cueni, Director General of IFPMA, the International Federation of Pharmaceutical Manufacturers and Associations.
Today, we face the first global pandemic in living memory. Never before has there been so much hope placed in finding safe and effective vaccines, with the promise that no one is left behind.
IFPMA’s members have worked for 20 years with Gavi to stem the ravages of infectious diseases. NOW they are working at unparalleled speed to develop and build manufacturing capacity and distribution networks to deploy a COVID-19 vaccine in record time. The pace and progress of this work is unprecedented.
We are proud to be a founding partners of the Gavi Alliance and the Vaccines Accelerator and are fully committed to its goal to accelerate development, production, and equitable access to safe, effective, and affordable COVID-19 vaccines.
Be assured, we will deliver on the shared vision to leave no one behind and win the battle against COVID-19 together.
Thank you.
About IFPMA
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.
Learn more
Related news and resources
The socio-economic value of adult immunisation programmes
Download this OHE report, commissioned by IFPMA, to learn more about the socio-economic value of adult vaccination programems on individual lives and societies at large.
Read more
Open letter from the biopharmaceutical industry to G20 Ministers in support of the advancement of the G20 Health Agenda
On 9 April 2024, IFPMA, Interfarma, and FIFARMA submitted an open letter to G20 Ministers in support of the advancement of the G20 Health Agenda. The letter is available for download in English, Portuguese, and Spanish.
Read moreThe socio-economic value of adult immunization (OHE)(Poster)
This study by the Office of Health Economics (OHE) synthesizes existing evidence for the broad, socio-economic value of adult immunization programs, focusing on influenza, pneumococcal, herpes zoster (HZ), and respiratory syncytial virus (RSV) programs in ten countries (Australia, Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand, United States). In a forthcoming publication, OHE will...
Read more